Changes to the Code
H.R. 767 · Fast-Track Logistics for Acquiring Supplies in a Hurry Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
FLASH Act of 2025
In committee · step 2 of 5
42 U.S.C. § 247d–7e Biomedical Advanced Research and Development Authority
4 changes the bill asks for here, 4 carried out
- Carried out:
in subsection (a)(6)(B), by amending clause (ii) to read as follows:
(ii) design and development of— (I) tests and prototypes, including obtaining sufficient quantities for evaluation of such tests and prototypes; and (II) models, including animal models, for such testing and prototypes;; and
- Carried out:
by redesignating clause (iv) as clause (v); and
- Carried out:
by inserting after clause (iii) the following new clause:
(iv) Follow-on production contracts or transactions.— (I) In general.— A transaction entered into under this subparagraph for the design or development of a prototype may provide for the award of a follow-on production contract or transaction to the participants in the …
- Carried out:
by adding at the end the following new subparagraphs:
(I) Procurement for experimental or test purposes.— (i) In general.— The Secretary may purchase medical countermeasures, products, and supplies, chemical materials and reagents, manufacturing supplies, protective equipment, and such other supplies, including parts and …
§ 247d–7e(a)(6)(B)Activities included(i)–(iv)
Start of § 247d–7e to (a)(6)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i) | (i) | (i) | ||
| testing of the product to determine whether the product may be approved, cleared, or licensed under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] or under section 262 of this title for a use that is or may be the basis for such product becoming a qualified countermeasure or qualified pandemic or epidemic product, or to help obtain such approval, clearance, or license; | testing of the product to determine whether the product may be approved, cleared, or licensed under the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 301 et seq.] or under section 262 of this title for a use that is or may be the basis for such product becoming a qualified countermeasure or qualified pandemic or epidemic product, or to help obtain such approval, clearance, or license; | |||
| (ii) | (ii) | (ii) | ||
| [inserted: design and development of—] | ||||
| (ii)(I) | (I) [inserted: ] | |||
| [inserted: tests and prototypes, including obtaining sufficient quantities for evaluation of such tests and prototypes; and] | ||||
| (ii)(II) | (II) [inserted: ] | |||
| [inserted: models, including animal models, for such testing and prototypes;] | ||||
| (ii) | ||||
| (iii) | (iii) | (iii) | ||
| activities to facilitate manufacture of the product on a commercial scale with consistently high quality, as well as to improve and make available new technologies to increase manufacturing surge capacity; | activities to facilitate manufacture of the product on a commercial scale with consistently high quality, as well as to improve and make available new technologies to increase manufacturing surge capacity; | |||
| (iv) | (iv) | (iv) | ||
| activities to support, maintain, and improve domestic manufacturing surge capacity and capabilities, as appropriate, including through the utilization of advanced manufacturing and platform technologies, to increase the availability of products that are or may become qualified countermeasures or qualified pandemic or epidemic products; | activities to support, maintain, and improve domestic manufacturing surge capacity and capabilities, as appropriate, including through the utilization of advanced manufacturing and platform technologies, to increase the availability of products that are or may become qualified countermeasures or qualified pandemic or epidemic products; | |||
§ 247d–7e(c)(5)Transaction authorities(A)–(B)
(a)(6)(B)(v)–(c)(5)(A)(iii) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(iii)(I) | (I) In general | (I) In general | ||
| Notwithstanding clause (ii), the Secretary, shall, to the maximum extent practicable, use competitive procedures when entering into transactions to carry out projects under this subsection for purposes of a public health emergency declared by the Secretary under section 247d of this title. Any such transactions entered into during such public health emergency shall not be terminated solely due to the expiration of such public health emergency, if such public health emergency ends before the completion of the terms of such agreement. | Notwithstanding clause (ii), the Secretary, shall, to the maximum extent practicable, use competitive procedures when entering into transactions to carry out projects under this subsection for purposes of a public health emergency declared by the Secretary under section 247d of this title. Any such transactions entered into during such public health emergency shall not be terminated solely due to the expiration of such public health emergency, if such public health emergency ends before the completion of the terms of such agreement. | |||
| (A)(iii)(II) | (II) Report | (II) Report | ||
| After the expiration of the public health emergency declared by the Secretary under section 247d of this title, the Secretary shall provide a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives regarding the use of any funds pursuant to the authority under subclause (I), including any outcomes, benefits, and risks associated with the use of such funds, and a description of the reasons for the use of such authority for the project or projects. | After the expiration of the public health emergency declared by the Secretary under section 247d of this title, the Secretary shall provide a report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives regarding the use of any funds pursuant to the authority under subclause (I), including any outcomes, benefits, and risks associated with the use of such funds, and a description of the reasons for the use of such authority for the project or projects. | |||
| (A)(iv) | (iv) [inserted: Follow-on production contracts or transactions.—] | |||
| (A)(iv)(I) | (I) [inserted: In general.—] | |||
| [inserted: A transaction entered into under this subparagraph for the design or development of a prototype may provide for the award of a follow-on production contract or transaction to the participants in the transaction.] | ||||
| (A)(iv)(II) | (II) [inserted: Prototype subprojects.—] | |||
| [inserted: A transaction entered into under this subparagraph includes all prototype subprojects awarded under the transaction to carry out authorities under this section.] | ||||
| (A)(iv)(III) | (III) [inserted: Exception to competitive procedures.—] | |||
| [inserted: Notwithstanding clause (ii), a follow-on production contract or transaction provided for in a transaction under this clause may be awarded to the participants in the transaction without the use of competitive procedures, even if explicit notification was not listed within the request for proposal for the transaction, if competitive procedures were used for the selection of parties for participation in the initial transaction.] | ||||
| (A)(v) | [inserted: (v)] Guidelines | |||
| The Secretary shall establish guidelines regarding the use of the authority under clause (i). Such guidelines shall include auditing requirements. | The Secretary shall establish guidelines regarding the use of the authority under clause (i). Such guidelines shall include auditing requirements. | |||
| (B) | (B) Expedited authorities | (B) Expedited authorities | ||
| (B)(i) | (i) In general | (i) In general | ||
| In awarding contracts, grants, and cooperative agreements, and in entering into other transactions under subparagraph (B) or (D) of paragraph (4), the Secretary shall have the expedited procurement authorities, the authority to expedite peer review, and the authority for personal services contracts, supplied by subsections (b), (c), and (d) of section 247d–6a of this title. | In awarding contracts, grants, and cooperative agreements, and in entering into other transactions under subparagraph (B) or (D) of paragraph (4), the Secretary shall have the expedited procurement authorities, the authority to expedite peer review, and the authority for personal services contracts, supplied by subsections (b), (c), and (d) of section 247d–6a of this title. | |||
§ 247d–7e(c)Biomedical Advanced Research and Development Authority(5)–(7)
(c)(5)(B)(ii)–(F) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (5)(G) | (G) Government purpose | (G) Government purpose | ||
| In awarding contracts, grants, and cooperative agreements under this section, the Secretary shall provide a clear statement of defined Government purpose related to activities included in subsection (a)(6)(B) for a qualified countermeasure or qualified pandemic or epidemic product. | In awarding contracts, grants, and cooperative agreements under this section, the Secretary shall provide a clear statement of defined Government purpose related to activities included in subsection (a)(6)(B) for a qualified countermeasure or qualified pandemic or epidemic product. | |||
| (5)(H) | (H) Supporting warm-base and surge capacity and capabilities | (H) Supporting warm-base and surge capacity and capabilities | ||
| Pursuant to an award under subparagraph (B)(v),1 the Secretary may make payments for activities necessary to maintain domestic manufacturing surge capacity and capabilities supported under such award to ensure that such capacity and capabilities are able to support the rapid manufacture of countermeasures as required by the Secretary to prepare for, or respond to, an existing or potential public health emergency or otherwise address threats that pose a significant level of risk to national security. The Secretary may support the utilization of such capacity and capabilities under awards for countermeasure and product advanced research and development, as appropriate, to provide for the maintenance of such capacity and capabilities. | Pursuant to an award under subparagraph (B)(v),1 the Secretary may make payments for activities necessary to maintain domestic manufacturing surge capacity and capabilities supported under such award to ensure that such capacity and capabilities are able to support the rapid manufacture of countermeasures as required by the Secretary to prepare for, or respond to, an existing or potential public health emergency or otherwise address threats that pose a significant level of risk to national security. The Secretary may support the utilization of such capacity and capabilities under awards for countermeasure and product advanced research and development, as appropriate, to provide for the maintenance of such capacity and capabilities. | |||
| (5)(I) | (I) [inserted: Procurement for experimental or test purposes.—] | |||
| (5)(I)(i) | (i) [inserted: In general.—] | |||
| [inserted: The Secretary may purchase medical countermeasures, products, and supplies, chemical materials and reagents, manufacturing supplies, protective equipment, and such other supplies, including parts and accessories, and designs thereof, as the Secretary determines necessary for experimental or test purposes in the development of supplies that are necessary for national public health and health security.] | ||||
| (5)(I)(ii) | (ii) [inserted: Procedures.—] | |||
| [inserted: Notwithstanding subparagraph (A)(ii), the Secretary may make purchases under this subparagraph by contract, or by entering into a transaction other than a contract, using noncompetitive procedures.] | ||||
| (5)(J) | (J) [inserted: Acquisition of innovative commercial products and commercial services using general solicitation competitive procedures.—] | |||
| (5)(J)(i) | (i) [inserted: In general.—] | |||
| [inserted: Notwithstanding subparagraph (A)(ii), the Secretary may acquire innovative commercial products and commercial services through a competitive selection of proposals resulting from a general solicitation and the peer review of such proposals.] | ||||
| (5)(J)(ii) | (ii) [inserted: Treatment as competitive procedures.—] | |||
| [inserted: Use of general solicitation competitive procedures under clause (i) shall be considered to be use of competitive procedures for purposes of chapter 33 of title 41, United States Code.] | ||||
| (5)(J)(iii) | (iii) [inserted: Limitations.—] | |||
| (5)(J)(iii)(I) | (I) [inserted: Transactions in excess of $100,000,000.—] | |||
| [inserted: The Secretary may not enter into a contract or agreement in excess of $100,000,000 using the authority under clause (i), unless the Secretary makes a written determination of the efficacy of the effort to meet mission needs of the Department of Health and Human Services.] | ||||
| (5)(J)(iii)(II) | (II) [inserted: Fixed-price.—] | |||
| [inserted: Contracts or agreements entered into using the authority under clause (i) shall be fixed-price, including fixed-price incentive contracts.] | ||||
| (5)(J)(iv) | (iv) [inserted: Congressional notification required.—] | |||
| (5)(J)(iv)(I) | (I) [inserted: Submission.—] | |||
| [inserted: Not later than 45 days after the award of a contract for an amount exceeding $100,000,000 using the authority under clause (i), the Secretary shall provide notification of such award to the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate.] | ||||
| (5)(J)(iv)(II) | (II) [inserted: Contents.—] | |||
| [inserted: Notification of an award under subclause (I) shall include the following:] | ||||
| (5)(J)(iv)(II)(aa) | (aa) [inserted: ] | |||
| [inserted: Description of the innovative commercial product or commercial service acquired.] | ||||
| (5)(J)(iv)(II)(bb) | (bb) [inserted: ] | |||
| [inserted: Description of the requirement, capability gap, or potential technological advancement with respect to which the innovative commercial product or commercial service acquired provides a solution or a potential new capability.] | ||||
| (5)(J)(iv)(II)(cc) | (cc) [inserted: ] | |||
| [inserted: Amount of the contract awarded.] | ||||
| (5)(J)(iv)(II)(dd) | (dd) [inserted: ] | |||
| [inserted: Identification of the contractor awarded the contract.] | ||||
| (5)(J)(v) | (v) [inserted: Innovative defined.—] | |||
| [inserted: In this subparagraph, the term “innovative”, with respect to a commercial product or commercial service, means—] | ||||
| (5)(J)(v)(I) | (I) [inserted: ] | |||
| [inserted: any technology, process, or method, including research and development, that is new as of the date of submission of a proposal; or] | ||||
| (5)(J)(v)(II) | (II) [inserted: ] | |||
| [inserted: with respect to a technology, process, or method, including research and development, existing as of the date of submission of a proposal, any application of such technology, process, or method that is new to the Federal Government as of such date.] | ||||
| (6) | (6) At-risk individuals | (6) At-risk individuals | ||
| In carrying out the functions under this section, the Secretary may give priority to the advanced research and development of qualified countermeasures and qualified pandemic or epidemic products that are likely to be safe and effective with respect to children, pregnant women, older adults, and other at-risk individuals with relevant characteristics that warrant consideration during the process of researching and developing such countermeasures and products. | In carrying out the functions under this section, the Secretary may give priority to the advanced research and development of qualified countermeasures and qualified pandemic or epidemic products that are likely to be safe and effective with respect to children, pregnant women, older adults, and other at-risk individuals with relevant characteristics that warrant consideration during the process of researching and developing such countermeasures and products. | |||
| (7) | (7) Personnel authorities | (7) Personnel authorities | ||
Rest of § 247d–7e unchanged